Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Trial Result Tables
View:
Post by Eoganacht on May 02, 2023 6:23pm

Trial Result Tables

Below are 3 trial result tables.None of the 3 tables include the phase 1 patients as it looks like Theralase will be presenting trial data without them from now on.

The first is from the ASCO presentation (29 Nov 22 results) but with the phase 1 patients removed.

The second is derived from the AUA presentation table and Swimmer's Plot. It includes the CR patients so that the ASCO results and AUA results can be compared.

The third is the same as the AUA table but with the first 12 undertreated patients removed. I believe this table most accurately reflects the efficacy of the treatment.


Assessed 90 Days 180 Days 270 Days 360 Days 350 Days
  % # % # % # % # % #
CR 53% 21 43% 15 38% 13 26% 8 23% 6
IR 15% 6 26% 9 21% 7 16% 5 12% 3
TR 68% 27 69% 24 59% 20 42% 13 35% 9
NR 32% 13 31% 11 41% 14 58% 18 65% 17
Evaluable  40 35 34 31 26

Results from ASCO Presentation minus phase 1 patients



Assessed 90 Days 180 Days 270 Days 360 Days 350 Days
  % # % # % # % # % #
CR 54% 28 49% 23 38% 15 24% 9 22% 8
IR 12% 6 17% 8 15% 6 5% 2 5% 2
TR 65% 34 66% 31 53% 21 29% 11 27% 10
NR 35% 18 34% 16 47% 19 71% 27 73% 27
Evaluable  52 47 40 38 37

Results from AUA Presentation including CR patients



Assessed 90 Days 180 Days 270 Days 360 Days 350 Days
  % # % # % # % # % #
CR 70% 28 66% 23 54% 15 35% 9 32% 8
IR 15% 6 23% 8 21% 6 8% 2 8% 2
TR 85% 34 89% 31 75% 21 42% 11 40% 10
NR 15% 6 11% 4 25% 7 58% 15 60% 15
Evaluable  40 35 28 26 25

Results from AUA Presentation including CR patients with the 12 undertreated patients removed
Comment by Infinity on May 02, 2023 6:30pm
Thanks Eoga,   This presentation has way more clarity.  I believe the last column on the right has a Typo,  should read 450 days instead of 350 days?
Comment by Eoganacht on May 02, 2023 6:32pm
Yes it was a typo - it should be 450. Thanks Infinity.
Comment by Rumpl3StiltSkin on May 02, 2023 6:37pm
Really like this Eoga, Nice Job
Comment by greaterfoolFred on May 02, 2023 7:33pm
 Good effort Eoganacht, and I hate to sound negative, because I am not, but is it true that all of the first 12 were NR at 450 days? Someone posted earlier that 2 of them were CR.
Comment by CancerSlayer on May 02, 2023 11:09pm
  Thanks Eoganacht.... When I look at the 4/26 Swimmer plot, there are 13 active patients (at different stages) who have been assessed at 90 days, plan to move forward with the trial & are awaiting their 360 day assessment.  Interestingly, 2 patients who had CR through 90 & 180 days are represented as currently being inactive. For the above subgroup of 13 patients, 11 of 13  ...more  
Comment by Eoganacht on May 03, 2023 12:04am
Thanks CancerSlayer - I think it's looking very good. A durable complete response of 30%-40% along with only one or two one hour treatments and no safety issues bodes very well indeed.
Comment by Rumpl3StiltSkin on May 03, 2023 9:02am
Does the 90 day data in the swimmers plot include the 2 CRs from phase 1? If not then I don't think there are 2 discounted CRs in the swim plot data. I don't think there were any  of the 12 undertreated that were CR? Maybe a few of them were IR? So IF I'm correct the worst we will have is that 35% 450 day CR  Slayer came up with. :-)
Comment by enriquesuave on May 03, 2023 9:23am
In the initial 12 under treated, there were 3 CR patients and 3 PR patients at 90 days.  I can still see between 40-55% CR depending on how IR Patients are reclassified and also if new CRs appear after 2nd treatment when all is said and done.  Anything above 30% for only 2 treatments 6 months apart and minimal side effects is still way better than Keytruda and Adstiladrin or any other ...more  
Comment by NotinKansas on May 03, 2023 12:34am
To identify the results achieved by the 12 initially undertreated one has to revisit the MD&A for full year 2021 (dated 28 April 2022). Here on page 5 they first present the results for all patients then treated, incl. those from Phase Ib (first table), and next the results for the optimized cohort alone, this time excl. Phase Ib (second table). If you deduct from the first table the two CRs ...more  
Comment by Rumpl3StiltSkin on May 03, 2023 9:06am
I stand corrected from my post below. There were some CRs from the 12 undertreated. Which to my thinking is even more encouraging. Makes the removal of these numbers from overall study seem more fair.
Comment by ScienceFirst on May 03, 2023 9:32am
Great digging NotinKansas.  Thanks for sharing.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250